论文部分内容阅读
本文用~(125)碘-苯妥英钠放免(PEG)分析法,研究6位志愿者服DPH(片)300mg的药代动学显示,5位志愿者DPH血浓度经时变化较规律,“AKAIKE”判别值显示两种药动学模型,主要参数值分别为,开放一室T_1/2kd=30.7053±31.9156(h),Vd=0.2471±0.02569(L/kg)。Cl=0.1112+0.009549(L/kg·h),AUC·~∞=791.7059±631.253(μg·h/ml);开放二室T_1/2β=27.9154±0.9312(h),Vd=0.2967±0.0084(L/kg),Cl=0.007373±0.O005(L/kg·h,AUC·~∞ =695.5453±213.773(μg·h/ml)。DPH唾药浓度经时变化不规律,与DPH血浓度相关不显著(P>0.05),用于药动学研究意义不大。
In this study, pharmacokinetics of 300 mg DPH tablets in 6 volunteers was studied by radioactive (125) iodine-phenytoin sodium (PEG) assay. The blood levels of DPH in 5 volunteers varied with time, and "AKAIKE The discriminant values showed two pharmacokinetic models. The main parameters were T 1 / 2kd = 30.7053 ± 31.9156 (h) and Vd = 0.2471 ± 0.02569 (L / kg) respectively. Cl = 0.1112 + 0.009549 (L / kg · h), AUC · ∞ = 791.7059 ± 631.253 (μg · h / ml); open two compartment T_1 / 2β = 27.9154 ± 0.9312 (h); Vd = 0.2967 ± 0.0084 /kg),Cl=0.007373 ± 0.O005 (L / kg · h, AUC · ∞∞ = 695.5453 ± 213.773 (μg · h / ml) .DCH salivary concentration changes irregularly over time, and DPH blood concentration is not related Significantly (P> 0.05), for pharmacokinetic study of little significance.